PharmaSurgics develops a novel pharmaceutical product for the prevention of post-surgical scar formation.
Encubator Portfolio Company from 2004.
PharmaSurgics develops novel treatments for the prevention of internal post-surgical scar formation, adhesions, which represent a problem of high unmet medical need.
The extensive problems associated with adhesions cause severe pain to millions of patients. It is also a world-wide dilemma for surgeons, and a major burden on health care systems.
Existing therapies have failed to show efficacy and have been associated with severe adverse effects or complicated handling.
Kjell Olmarker, Senior Advisor R&D
Mattias Munnich, Business Development Manager
PharmaSurgics is an Encubator Portfolio Company from CSE class of 2004.
Biotech
Inger Mattsby-Baltzer
Kjell Olmarker
+46 31-762 29 00
Arvid Wallgrens Backe 20, Gothenburg
Solution
Product for Scar Prevention
Unique product concept for scar prevention
PharmaSurgics’ peptides integrated into a lubricating vehicle covering all surfaces that are at risk of developing post surgical adhesions creates a state-of-the-art product for preventing adhesion formation. The combined effect of a physical barrier and a novel compound directly affecting the mechanism behind adhesion formation is unique. The product is designed to be easily applied before closure of a surgical incision and the concept is developed to be adaptable for several surgical procedures. The application of PharmaSurgics’ product in the flexor tendon indication is visualized to the left.
